Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), sold 17,537 shares at $233.46 ($4.0M) on 2026-05-29, disclosed to the SEC on 2026-06-02.
Scheduled sale ($4.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $233.46 | 6,000 | $1.4M | 34.8% |
| 2 | $230.30 | 6,000 | $1.4M | 34.4% |
| 3 | $223.39 | 5,537 | $1.2M | 30.8% |
| Total | $229.20 avg | 17,537 | $4.0M | 100% |
| Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |
| AXSM | SELL | 2025-05-20 | $322K | — | Filing → |